KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Source : https://www.sciencedirect.com/science/article/pii/S0169500221000647

Available online 13 February 2021 * CRISP prospectively collected real-world data on advanced NSCLC and KRAS mutations * Of 1,039 patients, 39.5% had KRAS mutations, 38.9% of these were KRAS G12C-mutated * KRAS G12C-mutated advanced NSCLC has poor outcome under current standard therapy * Valuable historical control for upcoming clinical studies on KRAS-inhibitors After decades of unsuccessful efforts in inhibiting KRAS, promising clinical data targeting the mutation subtype G12C emerge.